<?xml version="1.0" encoding="UTF-8"?>
<p>Chloroquine was first introduced in 1934. Hydroxychloroquine/chloroquine are both 4-aminoquinolones approved in the treatment of Malaria, Systemic Lupus Erythematosus, and Rheumatoid Arthritis [
 <xref rid="B103-antioxidants-09-00636" ref-type="bibr">103</xref>]. The FDA approved these drugs for “emergency use” in hospitalized patients with COVID-19 in March of 2020. Many proposals to use these drugs for coronavirus are based on in vitro and animal studies where they proved beneficial, the use of chloroquine was based on evidence of it being a potent inhibitor of SARS coronavirus infection and spread [
 <xref rid="B104-antioxidants-09-00636" ref-type="bibr">104</xref>]. The data for the prevention and treatment of severely ill patients have so far been disappointing. During the MERS epidemic, 4-aminoquinolones were shown to affect glycosylation of ACE-2 receptors, which is used by COVID-19 to enter cells [
 <xref rid="B104-antioxidants-09-00636" ref-type="bibr">104</xref>].
</p>
